# Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

> **NCT03071874** · PHASE2 · UNKNOWN · sponsor: **Massachusetts General Hospital** · enrollment: 28 (actual)

## Conditions studied

- Meningioma

## Interventions

- **DRUG:** AZD2014

## Key facts

- **NCT ID:** NCT03071874
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-17
- **Primary completion:** 2022-06-30
- **Final completion:** 2024-07-25
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-10-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071874, "Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03071874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*